http://www.thepharmaletter.comThe Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the Pharmaceuticals, Biotechnology and Generics sectors of the overall health care industry, backed by a team of respected writers with many years of experience in the field. Register for free for our daily email newsletter and to...Wed, 11 Jan 2012 13:04:46 +0100http://www.thepharmaletter.com/file/106921/united-drug-plans-to-cut-pharmaceutical-jobs.htmlIn what could be a major setback for Pharmaceutical Jobs, United Drug is reportedly seeking to lay off up to 150 workers from its Irish supply business. According to a report filed by irishtimes.com, United Drug confirmed it will seek up to 150 ...http://www.thepharmaletter.com/file/106921/united-drug-plans-to-cut-pharmaceutical-jobs.htmlTue, 30 Aug 2011 09:11:23 +0100http://www.thepharmaletter.com/file/106915/teva-gains-to-4-week-high-after-us-court-denies-motion-on-suit.htmlTeva Pharmaceutical Industries Ltd. (TEVA) climbed to the highest level in almost four weeks after a federal court denied a motion by Mylan Inc. to dismiss Teva's patent lawsuit on the multiple-sclerosis ...http://www.thepharmaletter.com/file/106915/teva-gains-to-4-week-high-after-us-court-denies-motion-on-suit.htmlTue, 30 Aug 2011 08:40:52 +0100http://www.thepharmaletter.com/file/106916/medivir-strengthens-its-management-team.htmlKrestic on Aug 30, 2011 in Featured, Pharmaceuticals Medivir AB (STO:MVIRB), an emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces several new appointments to its executive management team. ...http://www.thepharmaletter.com/file/106916/medivir-strengthens-its-management-team.htmlTue, 30 Aug 2011 08:13:49 +0100http://www.thepharmaletter.com/file/106902/biotechnology-summit-set-for-sept-21.htmlDr. Gene Hoyme of Sanford Health will be the keynote speaker at the 2011 South Dakota Biotechnology Summit & Annual Meeting: Investing in Biotechnology for Feed, Fuel and Heal, slated to be held Sept. 21 at the Ramkota Hotel and Conference Center in ...http://www.thepharmaletter.com/file/106902/biotechnology-summit-set-for-sept-21.htmlTue, 30 Aug 2011 08:10:50 +0100http://www.thepharmaletter.com/file/106903/10-biotech-stocks-being-dumped-by-big-money-managers.htmlCephalon Inc. (CEPH): Biotechnology Industry. Market cap of $6.27B. Net institutional shares sold over the current quarter at 13.2M, which is 18.67% of the company's 70.71M share float. Relatively low correlation to the market (beta = 0.38), ...http://www.thepharmaletter.com/file/106903/10-biotech-stocks-being-dumped-by-big-money-managers.htmlTue, 30 Aug 2011 05:44:50 +0100http://www.thepharmaletter.com/file/106901/area-teachers-attend-biotechnology-session-at-jcc.htmlJAMESTOWN - Biotechnology skills and techniques were the focus of a one-week training workshop at Jamestown Community College in August. Designed to provide area school teachers with key professional development in biotechnology, the program offered ...http://www.thepharmaletter.com/file/106901/area-teachers-attend-biotechnology-session-at-jcc.htmlTue, 30 Aug 2011 05:25:27 +0100http://www.thepharmaletter.com/file/106907/biotechcorp-to-draft-biomass-initiative-with-govt-agencies.htmlBy : The Star Malaysian Biotechnology Corp (BiotechCorp) is working with other government agencies and industry players to draft a biomass initiative which, among others, will ensure that the industry has sufficient raw materials. ...http://www.thepharmaletter.com/file/106907/biotechcorp-to-draft-biomass-initiative-with-govt-agencies.htmlTue, 30 Aug 2011 03:26:01 +0100http://www.thepharmaletter.com/file/106911/drug-hoarders-manufacturing-cuts-exacerbate-shortage-of-key-medications.htmlBETTY ANN BOWSER: About 60 percent of all the critical drugs in short supply are generic sterile injectables like these. They come from the drug manufacturers in self-contained doses, ready to be injected. They are mostly low-cost generics given in ...http://www.thepharmaletter.com/file/106911/drug-hoarders-manufacturing-cuts-exacerbate-shortage-of-key-medications.htmlTue, 30 Aug 2011 02:10:32 +0100http://www.thepharmaletter.com/file/106900/landesman-sees-spate-of-acquisitions-in-biotechnology.html29 (Bloomberg) -- Uri Landesman, president of Platinum Management LLC, talks about the outlook for consolidation in the biotechnology industry. Landesman also discusses prospects for Echo Therapeutics Inc. and his investment strategy. ...http://www.thepharmaletter.com/file/106900/landesman-sees-spate-of-acquisitions-in-biotechnology.htmlTue, 30 Aug 2011 01:15:43 +0100http://www.thepharmaletter.com/file/106909/generic-risks-should-be-reported-public-citizen-says.htmlFood and Drug Administration regulations should be revised so generic drug manufacturers can update product labels to warn patients about risks, Public Citizen said in a petition on Monday. Current FDA regulations stop generic ...http://www.thepharmaletter.com/file/106909/generic-risks-should-be-reported-public-citizen-says.htmlMon, 29 Aug 2011 23:18:33 +0100http://www.thepharmaletter.com/file/106923/president-wants-reduction-in-imported-pharmaceuticals.htmlHe was of the opinion that more pharmaceuticals needed to be produced locally in order to reduce the number of pharmaceutical items imported from foreign countries. The President made these observations at a discussion held at Temple Trees with a view ...http://www.thepharmaletter.com/file/106923/president-wants-reduction-in-imported-pharmaceuticals.htmlMon, 29 Aug 2011 20:42:53 +0100http://www.thepharmaletter.com/file/106906/medical-devices-outperform-market-but-rule-changes-loom.htmlTom Abate is an award-winning journalist who has covered biotechnology and health care for the San Francisco Chronicle. He is the author of "The Biotech Investor: How to Profit from the Coming Boom in Biotechnology" (2003, Times Books). ...http://www.thepharmaletter.com/file/106906/medical-devices-outperform-market-but-rule-changes-loom.htmlMon, 29 Aug 2011 20:02:16 +0100http://www.thepharmaletter.com/file/106904/start-up-research-firms-struggling-for-funds.htmlA yet-to-be-released global biotechnology report of the consultancy firm Ernst and Young (E&Y) says investors, both from public and private sources, prefer late-stage discoveries undertaken by large corporate houses in this high-risk and long-gestation ...http://www.thepharmaletter.com/file/106904/start-up-research-firms-struggling-for-funds.htmlMon, 29 Aug 2011 19:48:29 +0100http://www.thepharmaletter.com/file/106917/valeant-pharmaceuticals-boosts-stock-buyback-program-by-300m.htmlDrug maker Valeant Pharmaceuticals (TSE:VRX) said Monday its board has approved a $300 million increase in its share buyback program. Mississauga-based Valeant plans to repurchase up to $1.8 billion in senior notes, convertible notes and common shares. ...http://www.thepharmaletter.com/file/106917/valeant-pharmaceuticals-boosts-stock-buyback-program-by-300m.htmlMon, 29 Aug 2011 15:55:18 +0100http://www.thepharmaletter.com/file/106905/innovation-defies-bean-counters.htmlDefying measurement: Innovation, particularly in the biotechnology sector, is impossible to quantify. Photo: Erin Jonasson INNOVATION is one of those ambiguous things. A bit like originality or ingenuity. You know it when you see it but it's much ...http://www.thepharmaletter.com/file/106905/innovation-defies-bean-counters.htmlMon, 29 Aug 2011 14:54:44 +0100http://www.thepharmaletter.com/file/106922/top-50-pharmaceutical-companies-global.htmlThis report is an in-depth financial evaluation of the World's Top 50 largest Pharmaceutical Companies. Using the unique Plimsoll method of analysis, each of the top 50 Global Pharmaceutical Companies is individually assessed and ranked against each ...http://www.thepharmaletter.com/file/106922/top-50-pharmaceutical-companies-global.htmlMon, 29 Aug 2011 11:58:01 +0100http://www.thepharmaletter.com/file/106919/indias-piramal-eyes-15bn-overseas-deals.htmlAjay Piramal, chairman of the family-owned company, said that it planned to acquire several ailing midsized biotech companies and patents as well as enter joint ventures with big pharmaceutical groups that are struggling to develop new drugs in western ...http://www.thepharmaletter.com/file/106919/indias-piramal-eyes-15bn-overseas-deals.htmlMon, 29 Aug 2011 00:03:15 +0100http://www.thepharmaletter.com/file/106908/monsanto-corn-under-attack-by-superbug.htmlThe finding adds fuel to the race among crop biotechnology rivals to locate the next generation of genes that can protect plants from insects. Scientists at Monsanto and Syngenta AG of Basel, Switzerland, are already researching how to use a medical ...http://www.thepharmaletter.com/file/106908/monsanto-corn-under-attack-by-superbug.htmlSun, 28 Aug 2011 23:29:13 +0100http://www.thepharmaletter.com/file/106875/sagent-pharmaceuticals-inc-elects-jonathon-singer-as-chief-financial-officer.htmlAug 26, 2011 (M2 EQUITYBITES via COMTEX) -- Specialist pharmaceutical company Sagent Pharmaceuticals Inc SGNT revealed on Thursday the appointment of Jonathon Singer as its chief financial officer effective September. In the newly elected position, ...http://www.thepharmaletter.com/file/106875/sagent-pharmaceuticals-inc-elects-jonathon-singer-as-chief-financial-officer.htmlFri, 26 Aug 2011 09:05:55 +0100http://www.thepharmaletter.com/file/106868/indias-indoco-to-make-aspens-australia-generics.htmlMUMBAI (Reuters) - Mid-sized Indian drugmaker Indoco Remedies has signed a pact to make generic products sold by South Africa's Aspen Pharmacare in Australia, a top executive of the Indian firm said on Friday. Aspen Pharmacare in January acquired the ...http://www.thepharmaletter.com/file/106868/indias-indoco-to-make-aspens-australia-generics.htmlFri, 26 Aug 2011 08:17:36 +0100http://www.thepharmaletter.com/file/106871/indian-generics-drug-market-to-be-privileged-from-patent-expiries.htmlAs the key blockbusters go off-patent in future, the share of generics in Indian pharmaceutical market will reach to 80.5% by FY 2013, says RNCOS in its latest research report. Noida, UP -- (SBWIRE) -- 08252011 -- According to our new report, ...http://www.thepharmaletter.com/file/106871/indian-generics-drug-market-to-be-privileged-from-patent-expiries.htmlFri, 26 Aug 2011 05:56:55 +0100http://www.thepharmaletter.com/file/106870/the-shortage-of-vital-drugs.htmlSweeping consolidation in the generic drug industry means that fewer companies are left in that market to make up for a shortage. The shortages are forcing health care providers to buy more expensive products in the absence of cheap generics. ...http://www.thepharmaletter.com/file/106870/the-shortage-of-vital-drugs.htmlFri, 26 Aug 2011 03:01:09 +0100http://www.thepharmaletter.com/file/106877/china-nuokang-bio-pharmaceutical-q2-profit-down.html(RTTNews) - China Nuokang Bio-Pharmaceutical Inc. (NKBP: News ) Thursday reported net income for the second quarter of RMB 14.2 million or $2.2 million, compared with RMB 19.4 million or $2.9 million last year. Earnings per ADS dropped to RMB 0.72 or ...http://www.thepharmaletter.com/file/106877/china-nuokang-bio-pharmaceutical-q2-profit-down.htmlFri, 26 Aug 2011 01:11:04 +0100http://www.thepharmaletter.com/file/106860/vc-canvasses-more-biotech-research.htmlVICE-CHANCELLOR of Joseph Ayo Babalola University, JABU, Ikeji Arakeji, Ilesha, Osun State, Professor Sola Fajana, has called for more research on biotechnology to boost national development, saying the very essence of humanity depends on it. ...http://www.thepharmaletter.com/file/106860/vc-canvasses-more-biotech-research.htmlThu, 25 Aug 2011 21:59:56 +0100http://www.thepharmaletter.com/file/106863/us-india-business-council-roped-in-for-bangalore-biotech-show-next-year.htmlBusiness Line (From left) Mr Jagadish Patankar, MD, MM Activ Sci-tech Communication; Ms Kiran Mazumdar Shaw, Chairperson, Karnataka Vision Group on Biotechnology and MD, Biocon; Mr Sharat Chandra, Chairman, Institute of Bioinformatics and Applied ...http://www.thepharmaletter.com/file/106863/us-india-business-council-roped-in-for-bangalore-biotech-show-next-year.htmlThu, 25 Aug 2011 18:49:06 +0100http://www.thepharmaletter.com/file/106881/eastern-district-of-texas-deals-blow-to-generic-pharmaceutical-companies.htmlPar Pharmaceutical Inc., which Allergan case co-lead counsel Jonathan Singer said might be the only other Eastern District of Texas Hatch-Waxman ruling. Singer is a Minneapolis and San Diego partner who heads Fish & Richardson's pharmaceutical ...http://www.thepharmaletter.com/file/106881/eastern-district-of-texas-deals-blow-to-generic-pharmaceutical-companies.htmlThu, 25 Aug 2011 16:54:24 +0100http://www.thepharmaletter.com/file/106873/managing-bioequivalence-studies-to-optimize-the-quality-cost-and-speed-of-.html25, 2011 PRNewswire -- The global generics drug market has grown to $120 billion and with a number of blockbusters set to go off patent, the sector will see even more growth in the coming years. But as organizations involved in generics ramp up their ...http://www.thepharmaletter.com/file/106873/managing-bioequivalence-studies-to-optimize-the-quality-cost-and-speed-of-.htmlThu, 25 Aug 2011 15:51:08 +0100http://www.thepharmaletter.com/file/106879/hi-tech-pharmacal-acquires-rights-to-tussicapsr-extended-release-capsules-to-.htmlHi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of ...http://www.thepharmaletter.com/file/106879/hi-tech-pharmacal-acquires-rights-to-tussicapsr-extended-release-capsules-to-.htmlThu, 25 Aug 2011 13:05:50 +0100http://www.thepharmaletter.com/file/106834/generic-candesartan-launch-opportunity-prodrug-patent-expiration-in-2012.htmlGenericsWeb, the leader in established pharmaceutical patent analysis and searching, recently published an article based on its proprietary Pipeline Patent Intelligence that analyses opportunities in launching generic versions of Atacand (Candesartan ...http://www.thepharmaletter.com/file/106834/generic-candesartan-launch-opportunity-prodrug-patent-expiration-in-2012.htmlThu, 25 Aug 2011 08:24:22 +0100http://www.thepharmaletter.com/file/106835/drug-shortages-loom-large.htmlGeneric drugs made up a large proportion of the drugs in short supply, particularly older sterile injectables. The Pharmaceutical Research and Manufacturers of America (PhRMA) issued a statement in response, acknowledging the importance that generics ...http://www.thepharmaletter.com/file/106835/drug-shortages-loom-large.htmlThu, 25 Aug 2011 07:57:23 +0100http://www.thepharmaletter.com/file/106839/nearly-half-of-154m-settlement-going-to-texas.htmlAUSTIN, Texas (Legal Newsline) - Texas Attorney General Greg Abbott said Wednesday that the state will receive nearly $72 million as part of a multi-state settlement with Par Pharmaceutical Inc. In 2008, the Attorney General's ...http://www.thepharmaletter.com/file/106839/nearly-half-of-154m-settlement-going-to-texas.htmlWed, 24 Aug 2011 17:54:11 +0100http://www.thepharmaletter.com/file/106824/san-diegos-genomatica-a-pioneer-in-industrial-biotechnology-files-for-ipo.htmlThe San Diego company, which was founded in 1998, has emerged in recent years as a pioneer in industrial biotechnology. Using a proprietary software technology to model metabolic processes, the company has successfully demonstrated its ability to ...http://www.thepharmaletter.com/file/106824/san-diegos-genomatica-a-pioneer-in-industrial-biotechnology-files-for-ipo.htmlWed, 24 Aug 2011 17:09:25 +0100http://www.thepharmaletter.com/file/106844/market-movers-in-healthcare-include-siga-par-pharmaceutical-and-sanuwave.htmlThe Chairman and Chief Executive Officer of the the company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, Dr. Eric A. Rose commented, "This grant is a continuation of our vibrant, long-term relationship with ...http://www.thepharmaletter.com/file/106844/market-movers-in-healthcare-include-siga-par-pharmaceutical-and-sanuwave.htmlWed, 24 Aug 2011 17:01:35 +0100http://www.thepharmaletter.com/file/106836/prime-therapeutics-drug-trend-insights-reports-one-of-the-lowest-drug-spending-.htmlEvery 1 percent increase in the generic rate has the potential to deliver savings of 2 percent or more. Prime was able to increase its generic fill rate through benefit structures focused on making generics the most attractive option and member service ...http://www.thepharmaletter.com/file/106836/prime-therapeutics-drug-trend-insights-reports-one-of-the-lowest-drug-spending-.htmlWed, 24 Aug 2011 15:03:36 +0100http://www.thepharmaletter.com/file/106837/prasco-signs-pact-with-shionogi-to-market-generic-furadantin-oral-suspension.htmlPrasco Laboratories, the Authorized Generics company, announced it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Nitrofurantoin Oral Suspension, the Authorized Generic version of ...http://www.thepharmaletter.com/file/106837/prasco-signs-pact-with-shionogi-to-market-generic-furadantin-oral-suspension.htmlWed, 24 Aug 2011 13:46:32 +0100http://www.thepharmaletter.com/file/106825/workshop-on-biotechnology-held.htmlA biotechnology awareness creation workshop organised by the Sabima project with the theme, ?Strengthening capacity for safety biotechnology management in sub-Saharan Africa? is underway in Accra. Addressing participants at the opening of the workshop, ...http://www.thepharmaletter.com/file/106825/workshop-on-biotechnology-held.htmlWed, 24 Aug 2011 11:32:23 +0100http://www.thepharmaletter.com/file/106809/medicis-pharmaceutical-maintains-buy-rating-at-deutsche-bank.htmlAnalysts at Deutsche Bank retained a Buy rating on shares of Medicis Pharmaceutical Corp. (NYSE: MRX) as they believe the company is capable of generating 12 percent-plus long-term earnings per share growth, driven by its medical dermatology business, ...http://www.thepharmaletter.com/file/106809/medicis-pharmaceutical-maintains-buy-rating-at-deutsche-bank.htmlTue, 23 Aug 2011 20:55:55 +0100http://www.thepharmaletter.com/file/106804/generic-candesartan-launch-opportunity-prodrug-patent-expiration-in-2012.htmlPatent protection has expired in Canada and generics are available from Apotex, Sandoz and Teva, and generics have been identified in Australia despite the extended molecule patent remaining in force. ? In all major territories where Candesartan has ...http://www.thepharmaletter.com/file/106804/generic-candesartan-launch-opportunity-prodrug-patent-expiration-in-2012.htmlTue, 23 Aug 2011 16:35:07 +0100http://www.thepharmaletter.com/file/106802/simceres-branded-generic-formulation-biqi-passes-eu-gmp-inspection.htmlSimcere Pharmaceutical Group quoteszigman461866quotesnlsscr SCR -0.12% is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. ...http://www.thepharmaletter.com/file/106802/simceres-branded-generic-formulation-biqi-passes-eu-gmp-inspection.htmlTue, 23 Aug 2011 13:09:47 +0100http://www.thepharmaletter.com/file/106808/skystar-q2-revenue-up.htmlSkystar Bio-Pharmaceutical, a China-based manufacturer of veterinary medicines and vaccines, has reported net revenue of $10m for the second quarter ended 30 June 2011, compared to $8.26m for the same period in 2010. The company has posted a net income ...http://www.thepharmaletter.com/file/106808/skystar-q2-revenue-up.htmlTue, 23 Aug 2011 11:03:40 +0100http://www.thepharmaletter.com/file/106812/biocon-unit-signs-deal-for-clinical-research-with-us-company.htmlBiotech company Biocon stated that its division 'Clinigene International' has signed a deal with US-based Spaulding Clinical Research to mutually offer clinical research solutions to both pharmaceutical plus biotechnology companies. ...http://www.thepharmaletter.com/file/106812/biocon-unit-signs-deal-for-clinical-research-with-us-company.htmlTue, 23 Aug 2011 09:44:48 +0100http://www.thepharmaletter.com/file/106774/job-figure-for-cork-pharmaceutical-facility-raised-to-250.htmlA TOTAL of 250 jobs are to be created through the establishment of a pharmaceutical manufacturing facility in Carrigtwohill, Co Cork. Last month San Diego-based Sangart announced plans to hire 120 people at the facility in east Cork. ...http://www.thepharmaletter.com/file/106774/job-figure-for-cork-pharmaceutical-facility-raised-to-250.htmlTue, 23 Aug 2011 00:48:29 +0100http://www.thepharmaletter.com/file/106776/ftse-stops-the-rot-as-pharmaceuticals-bounce-back.htmlBut not all sectors performed quite as badly, with the pharmaceutical industry climbing by 3.09 per cent in total. GlaxoSmithKline was one of the key risers with an increase of 2.82 per cent as they prepared to snap up a 25 per cent minority share in ...http://www.thepharmaletter.com/file/106776/ftse-stops-the-rot-as-pharmaceuticals-bounce-back.htmlTue, 23 Aug 2011 00:48:17 +0100http://www.thepharmaletter.com/file/106827/generex-biotechnology-corporation-otcgnbt-ae37-update-unable-to-move-share-.htmlBy VFC's Stock House Generex Biotechnology Corporation (OTC:GNBT) subsidiary Antigen Express provided an update on its cancer immunotherapy AE37 last week, but the news ? which was the announcement of positive interim results ? failed to move the GNBT ...http://www.thepharmaletter.com/file/106827/generex-biotechnology-corporation-otcgnbt-ae37-update-unable-to-move-share-.htmlMon, 22 Aug 2011 23:34:26 +0100http://www.thepharmaletter.com/file/106767/prasco-to-sell-authorized-generic-of-shionogi-drug.htmlCINCINNATI ? Prasco will market an authorized generic drug for urinary tract infections under an agreement with Shionogi, the company said Monday. Prasco announced that it signed a supply agreement with Shinogi to market and distribute nitrofurantoin ...http://www.thepharmaletter.com/file/106767/prasco-to-sell-authorized-generic-of-shionogi-drug.htmlMon, 22 Aug 2011 16:59:13 +0100http://www.thepharmaletter.com/file/106768/generic-user-fees-could-boost-fda-inspection-powers.htmlGeneric drugmakers have forged a tentative deal with the US government that could see user fees being used to help the FDA inspect overseas active pharmaceutical ingredient manufacturing plants. The proposal could see almost $300 million in additional ...http://www.thepharmaletter.com/file/106768/generic-user-fees-could-boost-fda-inspection-powers.htmlMon, 22 Aug 2011 12:01:06 +0100http://www.thepharmaletter.com/file/106732/needham-teva-remains-top-dog-in-generics-pricing.html"Teva has taken a massive round of increases, the largest we can recall, on a basket of 60 mainly old line generics." Needham partly attributes the optimism that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) offers in its reiteration ...http://www.thepharmaletter.com/file/106732/needham-teva-remains-top-dog-in-generics-pricing.htmlSun, 21 Aug 2011 10:55:24 +0100http://www.thepharmaletter.com/file/106734/generic-drug-makers-may-soon-pay-for-inspection-of-overseas-plants.html(Nelson ChingBloomberg via Getty Images) One of the world's largest generic drug makers is calling on its fellow manufacturers to help foot the bill for the US Food and Drug Administration to conduct inspections of overseas pharmaceutical plants. ...http://www.thepharmaletter.com/file/106734/generic-drug-makers-may-soon-pay-for-inspection-of-overseas-plants.htmlTue, 16 Aug 2011 11:04:28 +0100http://www.thepharmaletter.com/file/106553/deal-in-place-for-inspecting-foreign-drugs.htmlAlthough branded drugs usually have more secure supply chains than those of generics, major pharmaceutical companies have moved aggressively into China in recent years and often rely on rarely inspected suppliers. Federal officials for years have ...http://www.thepharmaletter.com/file/106553/deal-in-place-for-inspecting-foreign-drugs.htmlSat, 13 Aug 2011 05:57:57 +0100